250 mg
Trade Name
Toxefro
Film-Coated tablet
Request Type
Registration
Drug Type
Biological Drug
Approval Date
SFDA Approved Use
Deferasirox is indicated for the treatment of chronic iron overload due to frequentblood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with betathalassemia major aged 6 years and older.
Deferasirox is also indicated for the treatment of chronic iron overload due to bloodtransfusions when deferoxamine therapy is contraindicated or inadequate in the followingpatient groups:
-in pediatric patients with beta thalassemia major with iron overload due tofrequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years
Deferasirox is also indicated for the treatment of chronic iron overload due to bloodtransfusions when deferoxamine therapy is contraindicated or inadequate in the followingpatient groups:
-in pediatric patients with beta thalassemia major with iron overload due tofrequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years